Tisotumab Vedotin Efficacious for Recurrent Cervical Cancer

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, July 8, 2024 -- Second- or third-line treatment with tisotumab vedotin is efficacious for patients with recurrent cervical cancer, according to a study published in the July 4 issue of the New England Journal of Medicine.

Ignace Vergote, M.D., Ph.D., from Universitaire Ziekenhuizen Leuven in Belgium, and colleagues conducted a phase 3, multinational, open-label trial of tisotumab vedotin as second- or third-line therapy in 502 patients with recurrent or metastatic cervical cancer. Participants were randomly assigned to receive tisotumab vedotin monotherapy (2.0 mg per kilogram of body weight every three weeks) or the investigator's choice of chemotherapy (253 and 249 patients, respectively).

The researchers found that median overall survival was significantly longer in the tisotumab vedotin group versus chemotherapy group, resulting in a lower risk for death (11.5 versus 9.5 months; hazard ratio, 0.70). Median progression-free survival was 4.2 versus 2.9 months for tisotumab vedotin versus chemotherapy (hazard ratio, 0.67). The confirmed objective response rate was 17.8 and 5.2 percent in the tisotumab vedotin and chemotherapy groups, respectively (odds ratio, 4.0). At least one adverse event that occurred during the treatment period was seen in 98.4 and 99.2 percent of patients in the tisotumab vedotin and chemotherapy groups, respectively; grade 3 or greater events occurred in 52.0 and 62.3 percent, respectively. Due to toxic effects, 14.8 percent of patients stopped tisotumab vedotin treatment.

"These data suggest that tisotumab vedotin may be a preferred second-line or third-line treatment option over chemotherapy for patients with recurrent cervical cancer," the authors write.

The study was funded by Genmab and Seagen, which was acquired by Pfizer in December 2023; tisotumab vedotin was codeveloped by Genmab and Pfizer.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-09 01:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords